Skip to main content
OpenTrials

Clinical trial condition

Urologic Neoplasms

Explore clinical trials studying Urologic Neoplasms. Study availability and eligibility vary by location and protocol.

2,952 public trials 630 recruiting studies
Refine in advanced search Browse all conditions

Urologic Neoplasms trial results

Active, Not Recruiting

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

NCT04090710

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Peter MacCallum Cancer Centre Melbourne, Australia
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Juravinski Cancer Centre Hamilton, Ontario, Canada
  • Grand River Regional Cancer Centre Kitchener, Ontario, Canada
View Trial Details
Active, Not Recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

NCT03213704

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +83 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 124 locations
View Trial Details
Active, Not Recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT03698994

Conditions
Advanced Malignant Solid Neoplasm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, +83 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 107 locations
View Trial Details
Active, Not Recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04320888

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, Female Urogenital Diseases, +85 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 174 locations
View Trial Details
Active, Not Recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

NCT03210714

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +74 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 116 locations
View Trial Details
Active, Not Recruiting

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

NCT04179162

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • Hartford Healthcare (Data Collection) Hartford, Connecticut, United States
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
View Trial Details
Active, Not Recruiting

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

NCT05092958

Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, +30 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Sutter Auburn Faith Hospital Auburn, California, United States
  • Alta Bates Summit Medical Center-Herrick Campus Berkeley, California, United States
  • Palo Alto Medical Foundation-Fremont Fremont, California, United States
View all 275 locations
View Trial Details
Active, Not Recruiting

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

NCT03375307

Conditions
Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Female Urogenital Diseases, +14 more
Locations
  • UC San Diego Health System - Encinitas Encinitas, California, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View all 17 locations
View Trial Details

Related conditions